| Year |
Citation |
Score |
| 2020 |
Qian JM, Martin AM, Martin K, Hammoudeh L, Catalano PJ, Hodi FS, Cagney DN, Haas-Kogan DA, Schoenfeld JD, Aizer AA. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. PMID 32926760 DOI: 10.1002/Cncr.33196 |
0.304 |
|
| 2020 |
Nathenson M, Choy E, Carr ND, Hibbard HD, Mazzola E, Catalano PJ, Thornton KA, Morgan JA, Cote GM, Merriam P, Wagner AJ, Demetri GD, George S. Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort. Journal of Clinical Oncology. 38: 11559-11559. DOI: 10.1200/Jco.2020.38.15_Suppl.11559 |
0.342 |
|
| 2020 |
Schoenfeld J, Hanna G, Jo V, Criscitiello S, Rawal B, Catalano P, Chau N, Lorch J, Kass J, Annino D, Goguen L, Ross B, Margalit D, Tishler R, Uppaluri R, et al. Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer International Journal of Radiation Oncology*Biology*Physics. 106: 1114. DOI: 10.1016/J.Ijrobp.2019.11.388 |
0.32 |
|
| 2019 |
Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, et al. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The Oncologist. PMID 31852811 DOI: 10.1634/Theoncologist.2019-0437 |
0.364 |
|
| 2019 |
Gibson MK, Catalano P, Kleinberg LR, Staley CA, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB. Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). The Oncologist. PMID 31227647 DOI: 10.1634/Theoncologist.2018-0750 |
0.322 |
|
| 2019 |
Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, et al. A phase I study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate- and high-risk patients with resected squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics. PMID 31082494 DOI: 10.1016/J.Ijrobp.2019.04.034 |
0.314 |
|
| 2019 |
Cagney DN, Lamba N, Sinha S, Catalano PJ, Bi WL, Alexander BM, Aizer AA. Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. Jama Oncology. PMID 30844036 DOI: 10.1001/Jamaoncol.2018.7204 |
0.301 |
|
| 2019 |
Kline C, Schoenfeld JD, Catalano PJ, Li J, Paccaly AJ, Sims TN, Bredlau A, Prados M, Haas-Kogan D, Mueller S. RBTT-09. A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS Neuro-Oncology. 21: vi220-vi220. DOI: 10.1093/Neuonc/Noz175.921 |
0.357 |
|
| 2018 |
Hochster H, Catalano PJ, O'Dwyer PJ, Mitchell EP, Jill Cohen D, Andrew Faller B, Kortmansky JS, Mehta Kircher S, Lacy J, Lenz HJ, Verma UN, Bowen Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v110. PMID 32177014 DOI: 10.1200/Jco.2018.36.15_Suppl.3504 |
0.3 |
|
| 2018 |
White MN, Dotan E, Catalano PJ, Cardin DB, Berlin JD. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. Journal of Geriatric Oncology. PMID 30573201 DOI: 10.1016/J.Jgo.2018.11.001 |
0.339 |
|
| 2018 |
Lamba N, Cagney DN, Brigell RH, Martin AM, Besse LA, Catalano PJ, Phillips JG, Pashtan IM, Bi WL, Claus EB, Golby AJ, Dunn IF, Smith TR, Tanguturi SK, Haas-Kogan DA, et al. Neurosurgical resection and stereotactic radiation versus stereotactic radiation alone in patients with a single or solitary brain metastasis. World Neurosurgery. PMID 30471438 DOI: 10.1016/J.Wneu.2018.11.100 |
0.337 |
|
| 2018 |
Cagney DN, Martin AM, Catalano PJ, Brown PD, Alexander BM, Lin NU, Aizer AA. Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer. Jama Oncology. PMID 29799956 DOI: 10.1001/Jamaoncol.2018.0813 |
0.301 |
|
| 2018 |
Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, et al. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 29398153 DOI: 10.1016/J.Radonc.2018.01.005 |
0.306 |
|
| 2018 |
Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, Aizer AA. Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. Jama Oncology. PMID 29327059 DOI: 10.1001/Jamaoncol.2017.3993 |
0.32 |
|
| 2017 |
Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer. PMID 29211295 DOI: 10.1002/Cncr.30967 |
0.332 |
|
| 2017 |
Diao K, Chen YH, Catalano PJ, Lee S, Milani N, Killoran JH, Baldini EH, Chen AB, Kozono DE, Mak RH. Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 29102264 DOI: 10.1016/J.Radonc.2017.10.002 |
0.3 |
|
| 2017 |
Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson Iii AB, Blackstock AW. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology. PMID 29040974 DOI: 10.1159/000480295 |
0.365 |
|
| 2017 |
Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB. Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncology. 73: 160-165. PMID 28939070 DOI: 10.1016/J.Oraloncology.2017.08.012 |
0.306 |
|
| 2017 |
Kamran SC, Manuel MM, Catalano P, Cho L, Damato AL, Lee LJ, Schmidt EJ, Viswanathan AN. MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer. Brachytherapy. PMID 28823395 DOI: 10.1016/J.Brachy.2017.07.007 |
0.317 |
|
| 2017 |
Zhao R, Catalano P, DeGruttola VG, Michor F. Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. Plos One. 12: e0180756. PMID 28723910 DOI: 10.1371/Journal.Pone.0180756 |
0.335 |
|
| 2017 |
Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, et al. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28662869 DOI: 10.1016/J.Radonc.2017.06.006 |
0.317 |
|
| 2017 |
Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus. 30: 1-8. PMID 28475728 DOI: 10.1093/Dote/Dox025 |
0.38 |
|
| 2017 |
Flaherty S, Barysauskas C, Catalano PJ. The patient experience: Patient characteristic differences in response. Journal of Clinical Oncology. 35: 144-144. DOI: 10.1200/Jco.2017.35.8_Suppl.144 |
0.303 |
|
| 2017 |
Kasozi RN, Choudhary A, Gibson MK, Catalano PJ, Kleinberg L, Staley CA, Sokoll LJ, Song W, Mulcahy MF, Leichman LP, Benson AB. ARDS in the setting of FOLFOX/cetuximab based chemoradiotherapy for locally advanced esophageal adenocarcinoma (E2205). Journal of Clinical Oncology. 35: 121-121. DOI: 10.1200/Jco.2017.35.4_Suppl.121 |
0.317 |
|
| 2017 |
Sahai V, Catalano PJ, Lubner SJ, Menge MR, Munshi HG, Nimeiri HS, Benson AB, O'Dwyer PJ. PrE0204: A multi-institutional, single arm, two-stage phase II trial of nab-paclitaxel and gemcitabine for first-line treatment of patients with advanced or metastatic cholangiocarcinoma—A PrECOG LLC study. Journal of Clinical Oncology. 35: 4072-4072. DOI: 10.1200/Jco.2017.35.15_Suppl.4072 |
0.355 |
|
| 2016 |
Cho LP, Manuel M, Catalano P, Lee L, Damato AL, Cormack RA, Buzurovic I, Bhagwat M, O'Farrell D, Devlin PM, Viswanathan AN. Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience. Gynecologic Oncology. PMID 27720445 DOI: 10.1016/J.Ygyno.2016.09.017 |
0.317 |
|
| 2016 |
Mak RH, Hermann G, Aerts H, Chen AB, Baldini EH, Kozono DE, Chen YH, Catalano PJ, Janne P. Outcomes by EGFR, KRAS and ALK Genotype After Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S156. PMID 27675664 DOI: 10.1016/J.Ijrobp.2016.06.378 |
0.302 |
|
| 2016 |
Rahman R, Catalano PJ, Arvold ND, Aizer AA, Weiss SE, Pinnell N, Horvath MC, Christianson L, Reardon DA, Lee EQ, Nayak L, Rinne M, Dunn IF, Golby AJ, Johnson MD, et al. Chemoradiation-Related Lymphopenia Is Common Among Glioblastoma Patients and Is Associated With Worse Progression-Free and Overall Survival. International Journal of Radiation Oncology, Biology, Physics. 96: E123. PMID 27673836 DOI: 10.1016/J.Ijrobp.2016.06.2512 |
0.308 |
|
| 2016 |
Sun F, Skolny MN, Swaroop MN, Rawal B, Catalano PJ, Brunelle CL, Miller CL, Taghian AG. The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Research and Treatment. PMID 27154787 DOI: 10.1007/S10549-016-3821-0 |
0.338 |
|
| 2016 |
Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. International Journal of Radiation Oncology, Biology, Physics. 94: 738-46. PMID 26972646 DOI: 10.1016/J.Ijrobp.2015.12.009 |
0.328 |
|
| 2016 |
Eads JR, Catalano PJ, Fisher GA, Klimstra DS, Zhang Z, Rubin D, Iagaru A, Wong TZ, O'Dwyer PJ. Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142). Journal of Clinical Oncology. 34: TPS4149-TPS4149. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps4149 |
0.331 |
|
| 2016 |
Benson AB, Zhao F, Meropol NJ, Catalano PJ, Chakravarthy B, Flynn PJ, Catalano RB, Giantonio BJ, Mitchell EP, Haller DG, Leichman CG, Petrelli NJ, Sinicrope FA, Tepper JE, Brierley JD, et al. Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. Journal of Clinical Oncology. 34: 3616-3616. DOI: 10.1200/Jco.2016.34.15_Suppl.3616 |
0.354 |
|
| 2016 |
Margalit D, Schoenfeld J, Rawal B, Puzanov M, Haddad R, Rabinowits G, Chau N, Lorch J, Lavigne A, Goguen L, Annino D, Thomas T, Catalano P, Tishler R. Patient Immunosuppression and the Association With Cancer-Specific Outcomes After Treatment of Squamous Cell Carcinoma of the Oropharynx International Journal of Radiation Oncology*Biology*Physics. 94: 913. DOI: 10.1016/J.Ijrobp.2015.12.145 |
0.337 |
|
| 2015 |
Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. Journal For Immunotherapy of Cancer. 3: 50. PMID 26672895 DOI: 10.1186/S40425-015-0095-8 |
0.341 |
|
| 2015 |
Mitra D, Catalano PJ, Cimbak N, Damato AL, Muto MG, Viswanathan A. The risk of lymphedema after post-operative radiation therapy in endometrial cancer. Journal of Gynecologic Oncology. PMID 26463430 DOI: 10.3802/Jgo.2016.27.E4 |
0.332 |
|
| 2015 |
Tanguturi SK, Lyatskaya Y, Chen Y, Catalano PJ, Chen MH, Yeo WP, Marques A, Truong L, Yeh M, Orlina L, Wong JS, Punglia RS, Bellon JR. Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Practical Radiation Oncology. PMID 26231594 DOI: 10.1016/J.Ijrobp.2015.07.554 |
0.315 |
|
| 2015 |
Mitra D, Nout R, Catalano PJ, Creutzberg C, Cimbak N, Lee L, Viswanathan AN. Rectal bleeding after radiation therapy for endometrial cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 115: 240-5. PMID 26003340 DOI: 10.1016/J.Radonc.2015.03.030 |
0.33 |
|
| 2015 |
Tseng YD, Chen YH, Catalano PJ, Ng A. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics. 91: 223-31. PMID 25835625 DOI: 10.1016/J.Ijrobp.2014.09.041 |
0.321 |
|
| 2015 |
Hochster HS, Catalano PJ, Mitchell EP, Cohen DJ, O'Dwyer PJ, Benson AB. E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC). Journal of Clinical Oncology. 33: TPS793-TPS793. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps793 |
0.317 |
|
| 2015 |
Kunz PL, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Schrijver I, Reidy DL, Strosberg JR, O'Dwyer PJ, Benson AB. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology. 33: TPS4145-TPS4145. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps4145 |
0.307 |
|
| 2015 |
Niu N, Catalano P, Enzinger P, Bueno R, King B, Martin N, Kimmelman A, Hong T, Wo J, Mamon H. A Retrospective Comparison of Neoadjuvant Chemoradiation Therapy Regimens for Locally Advanced Esophageal Cancer International Journal of Radiation Oncology*Biology*Physics. 93: E139. DOI: 10.1016/J.Ijrobp.2015.07.902 |
0.328 |
|
| 2014 |
Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4176-85. PMID 24914040 DOI: 10.1158/1078-0432.Ccr-13-2024 |
0.365 |
|
| 2014 |
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. American Journal of Clinical Oncology. PMID 24685886 DOI: 10.1097/Coc.0000000000000068 |
0.361 |
|
| 2014 |
Patel SA, Chen YH, Hornick JL, Catalano P, Nowak JA, Zukerberg LR, Bleday R, Shellito PC, Hong TS, Mamon HJ. Early-stage rectal cancer: clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection. Diseases of the Colon and Rectum. 57: 449-59. PMID 24608301 DOI: 10.1097/Dcr.0B013E3182A70709 |
0.345 |
|
| 2014 |
Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer. 120: 134-41. PMID 24122413 DOI: 10.1002/Cncr.28408 |
0.331 |
|
| 2014 |
Cohen SJ, Feng Y, Catalano PJ, Mitchell EP, O'Dwyer PJ, Lubner SJ, Fisher GA, Mulcahy MF, Burtness B, Benson AB. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. Journal of Clinical Oncology. 32: 4020-4020. DOI: 10.1200/Jco.2014.32.15_Suppl.4020 |
0.318 |
|
| 2014 |
Mitchell EP, Catalano PJ, Giantonio BJ, O'Dwyer PJ, Meropol NJ, Benson AB, Hamilton SR. CpG island methylator phenotype (CIMP) and outcome differences for African Americans (AA) and Caucasians (C) treated with FOLFOX4 or the combination with bevacizumab (B) in patients (pts) with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group study E3200. Journal of Clinical Oncology. 32: 3605-3605. DOI: 10.1200/Jco.2014.32.15_Suppl.3605 |
0.366 |
|
| 2014 |
Keane F, Chen Y, Neville B, Tishler R, Schoenfeld J, Catalano P, Margalit D. The Prognostic Significance of T-Stage and N-Stage in Patients With Squamous Cell Carcinoma of the Oropharynx (OPSCC) in the HPV Era International Journal of Radiation Oncology*Biology*Physics. 90: S513. DOI: 10.1016/J.Ijrobp.2014.05.1573 |
0.312 |
|
| 2014 |
Margalit D, Catalano P, Annino D, Goguen L, Norris C, Lorch J, Haddad R, Sher D, Tishler R. Toxicity and Survival After Reirradiation (reRT) With IMRT for Recurrent Squamous Cell Cancer of the Head and Neck (SCCHN) International Journal of Radiation Oncology*Biology*Physics. 88: 506. DOI: 10.1016/J.Ijrobp.2013.11.138 |
0.321 |
|
| 2013 |
Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. Journal of the National Cancer Institute. 105: 1600-7. PMID 24108812 DOI: 10.1093/Jnci/Djt270 |
0.383 |
|
| 2013 |
Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouché O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. Journal of the National Cancer Institute. 105: 1667-70. PMID 24108811 DOI: 10.1093/Jnci/Djt269 |
0.334 |
|
| 2013 |
Fouad MN, Lee JY, Catalano PJ, Vogt TM, Zafar SY, West DW, Simon C, Klabunde CN, Kahn KL, Weeks JC, Kiefe CI. Enrollment of patients with lung and colorectal cancers onto clinical trials. Journal of Oncology Practice / American Society of Clinical Oncology. 9: e40-7. PMID 23814523 DOI: 10.1200/Jop.2012.000598 |
0.332 |
|
| 2013 |
Chapman JW, O'Callaghan CJ, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ. Innovative estimation of survival using log-normal survival modelling on ACCENT database. British Journal of Cancer. 108: 784-90. PMID 23385733 DOI: 10.1038/Bjc.2013.34 |
0.327 |
|
| 2013 |
Najita JS, Catalano PJ. On determining the BMD from multiple outcomes in developmental toxicity studies when one outcome is intentionally missing. Risk Analysis : An Official Publication of the Society For Risk Analysis. 33: 1500-9. PMID 23231656 DOI: 10.1111/J.1539-6924.2012.01939.X |
0.664 |
|
| 2013 |
Zafar SY, Malin JL, Grambow SC, Abbott DH, Kolimaga JT, Zullig LL, Weeks JC, Ayanian JZ, Kahn KL, Ganz PA, Catalano PJ, West DW, Provenzale D. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer. 119: 854-62. PMID 22972673 DOI: 10.1002/Cncr.27815 |
0.358 |
|
| 2013 |
Catalano PJ, Ayanian JZ, Weeks JC, Kahn KL, Landrum MB, Zaslavsky AM, Lee J, Pendergast J, Harrington DP. Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Medical Care. 51: e9-15. PMID 22406968 DOI: 10.1097/Mlr.0B013E318222A711 |
0.313 |
|
| 2013 |
Patel SA, Chen Y, Hornick JL, Catalano PJ, Nowak J, Zukerberg LR, Hong TS, Mamon HJ. Prognostic markers of time to local recurrence and overall survival in early-stage rectal cancer. Journal of Clinical Oncology. 31: 473-473. DOI: 10.1200/Jco.2013.31.4_Suppl.473 |
0.355 |
|
| 2013 |
Nimeiri HS, Feng Y, Catalano PJ, Meropol NJ, Giantonio BJ, Sigurdson ER, Martenson JA, Whitehead RP, Sinicrope FA, Mayer RJ, O'Dwyer PJ, Benson AB. Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E14711 |
0.338 |
|
| 2013 |
Mitin T, Chen Y, Catalano PJ, Floyd SR, Kasper EM, Mahadevan A. The role of systemic disease status in treatment outcomes for patients with newly diagnosed brain oligometastases and treated with stereotactic radiosurgery alone Journal of Radiation Oncology. 3: 43-48. DOI: 10.1007/S13566-013-0116-5 |
0.329 |
|
| 2012 |
Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ. Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 545. PMID 27983263 DOI: 10.1200/Jco.2012.30.4_Suppl.545 |
0.329 |
|
| 2012 |
Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6384-91. PMID 23104894 DOI: 10.1158/1078-0432.Ccr-12-2223 |
0.331 |
|
| 2012 |
Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients' expectations about effects of chemotherapy for advanced cancer. The New England Journal of Medicine. 367: 1616-25. PMID 23094723 DOI: 10.1056/Nejmoa1204410 |
0.347 |
|
| 2012 |
Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the implementation of surveillance for stage I testicular seminoma. International Journal of Radiation Oncology, Biology, Physics. 84: 383-9. PMID 22349043 DOI: 10.1016/J.Ijrobp.2011.11.064 |
0.303 |
|
| 2012 |
Garg M, Lee JY, Kachnic LA, Catalano PJ, Henry DH, Cooley TP, Ratner L, Wachsman W, Aboulafia DM, Benson AB, Palefsky J, Whittington R, Mitsuyasu RT, Sparano JA. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. Journal of Clinical Oncology. 30: 4030-4030. DOI: 10.1200/Jco.2012.30.15_Suppl.4030 |
0.313 |
|
| 2012 |
Krishnan M, Epstein-Peterson Z, Chen Y, Catalano P, Chen J, Balboni T. Factors Predicting Life Expectancy in Patients With Metastatic Cancer Receiving Palliative Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 84: S52. DOI: 10.1016/J.Ijrobp.2012.07.344 |
0.362 |
|
| 2011 |
Chapman JW, O'Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ. Comparison of innovative estimation of efficacy to standard using the ACCENT database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3616. PMID 28020847 DOI: 10.1200/Jco.2011.29.15_Suppl.3616 |
0.316 |
|
| 2011 |
Zafar SY, Malin JL, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, et al. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. Bmc Cancer. 11: 354. PMID 21846341 DOI: 10.1186/1471-2407-11-354 |
0.311 |
|
| 2011 |
Chakravarthy AB, Catalano PJ, Martenson JA, Mondschein JK, Wagner H, Mansour EG, Talamonti MS, Benson AB. Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). International Journal of Radiation Oncology, Biology, Physics. 81: e607-13. PMID 21514072 DOI: 10.1016/J.Ijrobp.2011.02.042 |
0.357 |
|
| 2011 |
Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemotherapy and Pharmacology. 68: 863-70. PMID 21286719 DOI: 10.1007/S00280-011-1556-5 |
0.301 |
|
| 2011 |
Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy Annals of Oncology. 22: 979-984. PMID 20935059 DOI: 10.1093/Annonc/Mdq548 |
0.363 |
|
| 2011 |
Chakravarthy A, Catalano P, Mondschein J, Rosenthal D, Haller D, Whittington R, Wagner H, Sigurdson E, Mulcahy M, Benson A. A Phase II Trial of Neoadjuvant Paclitaxel/Cisplatin Chemotherapy followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/leucovorin (FU/LV) for Gastric Cancer (ECOG E7296) International Journal of Radiation Oncology*Biology*Physics. 81: S67. DOI: 10.1016/J.Ijrobp.2011.06.134 |
0.322 |
|
| 2010 |
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. Journal of Surgical Oncology. 101: 587-92. PMID 20461765 DOI: 10.1002/Jso.21527 |
0.353 |
|
| 2010 |
Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2947-51. PMID 20458043 DOI: 10.1200/Jco.2009.27.7988 |
0.316 |
|
| 2010 |
Gibson MK, Catalano PJ, Kleinberg L, Staley CA, Montgomery E, Song W, Mulcahy MF, Leichman LP, Benson AB. E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. Journal of Clinical Oncology. 28: 4064-4064. DOI: 10.1200/Jco.2010.28.15_Suppl.4064 |
0.3 |
|
| 2010 |
Margalit D, Sreedhara M, Chen Y, Catalano P, Nguyen P, Harris J, Brock J. Microinvasive Breast Cancer: Incidence of Axillary Metastases at Diagnosis and Recurrence Rates after Breast-conserving Therapy (BCT) or Mastectomy International Journal of Radiation Oncology*Biology*Physics. 78: S222. DOI: 10.1016/J.Ijrobp.2010.07.532 |
0.302 |
|
| 2010 |
Khimani N, Ng A, Chen Y, Catalano P, Silver B, Mauch P. Salvage Radiotherapy in Patients with Recurrent or Refractory CNS Lymphoma International Journal of Radiation Oncology*Biology*Physics. 78: S547-S548. DOI: 10.1016/J.Ijrobp.2010.07.1277 |
0.314 |
|
| 2009 |
Luketich J, Pennathur A, Catalano PJ, Swanson SJ, de Hoyos AL, Maddaus MA, Nguyen N, Benson AB, Fernando HC. Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4516. PMID 27962698 DOI: 10.1200/Jco.2009.27.15_Suppl.4516 |
0.304 |
|
| 2009 |
Najita JS, Li Y, Catalano PJ. A Novel Application of a Bivariate Regression Model for Binary and Continuous Outcomes to Studies of Fetal Toxicity. Journal of the Royal Statistical Society. Series C, Applied Statistics. 58: 555-573. PMID 20357904 DOI: 10.1111/J.1467-9876.2009.00667.X |
0.658 |
|
| 2009 |
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3778-85. PMID 19581537 DOI: 10.1200/Jco.2008.20.9007 |
0.309 |
|
| 2009 |
Jenab-Wolcott J, Catalano PJ, Fillingham B, Ferriere M, O'Dwyer PJ, Giantonio BJ. Voluntary submission of biological specimens from cancer clinical trials: An update of the Eastern Cooperative Oncology Group experience Journal of Clinical Oncology. 27: 6597-6597. DOI: 10.1200/Jco.2009.27.15_Suppl.6597 |
0.31 |
|
| 2009 |
Chakravarthy A, Catalano P, Martenson J, Mondschein J, Wagner H, Schuchter L, Mansour E, Talamonti M, Benson A. Long-term Follow-up of ECOG E4292: A Phase II Trial of High Dose Radiation with Concurrent 5-Fluorouracil and Cisplatin in Patients with Anal Cancer International Journal of Radiation Oncology*Biology*Physics. 75: S27. DOI: 10.1016/J.Ijrobp.2009.07.085 |
0.334 |
|
| 2008 |
Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, Benson AB. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. International Journal of Radiation Oncology, Biology, Physics. 72: 108-13. PMID 18722265 DOI: 10.1016/J.Ijrobp.2008.05.054 |
0.32 |
|
| 2008 |
Fouad M, Lee J, Kiefe CI, Catalano P, Vogt T. Why do cancer patients rarely participate in clinical trials? Journal of Clinical Oncology. 26: 6561-6561. DOI: 10.1200/Jco.2008.26.15_Suppl.6561 |
0.311 |
|
| 2007 |
Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6093-8. PMID 17947473 DOI: 10.1158/1078-0432.Ccr-07-1011 |
0.352 |
|
| 2007 |
Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4569-74. PMID 17876008 DOI: 10.1200/Jco.2006.10.4323 |
0.345 |
|
| 2007 |
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1539-44. PMID 17442997 DOI: 10.1200/Jco.2006.09.6305 |
0.358 |
|
| 2007 |
Catalano PJ, Mitchell EP, Giantonio BJ, Meropol NJ, Benson AB. Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200 Journal of Clinical Oncology. 25: 4100-4100. DOI: 10.1200/Jco.2007.25.18_Suppl.4100 |
0.389 |
|
| 2007 |
Giantonio BJ, Meropol NJ, Catalano PJ, Ng V, Oliver R, Sirzen F, Leonard S, Cassidy J, Benson AB. Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies Journal of Clinical Oncology. 25: 4073-4073. DOI: 10.1200/Jco.2007.25.18_Suppl.4073 |
0.358 |
|
| 2006 |
Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the eastern cooperative oncology group study E2200 Annals of Oncology. 17: 1399-1403. PMID 16873427 DOI: 10.1093/Annonc/Mdl161 |
0.365 |
|
| 2006 |
Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, Haller D. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Investigational New Drugs. 24: 447-54. PMID 16763788 DOI: 10.1007/S10637-006-7667-X |
0.371 |
|
| 2006 |
Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 14: 837-48. PMID 16482448 DOI: 10.1007/S00520-005-0902-8 |
0.339 |
|
| 2006 |
Giantonio BJ, Catalano PJ, O’Dwyer PJ, Meropol NJ, Benson AB. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group’s Study E3200 Journal of Clinical Oncology. 24: 3538-3538. DOI: 10.1200/Jco.2006.24.18_Suppl.3538 |
0.351 |
|
| 2005 |
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2. PMID 27946619 DOI: 10.1200/Jco.2005.23.16_Suppl.2 |
0.334 |
|
| 2005 |
Johnston PG, Benson A, Catalano P, Eapen S, Wolmark N, Sargent D, Mc Dermott U, Colangelo L, Wieand S, Goldberg R, Allegra C. The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3510. PMID 27944396 DOI: 10.1200/Jco.2005.23.16_Suppl.3510 |
0.321 |
|
| 2005 |
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8671-8. PMID 16314627 DOI: 10.1200/Jco.2004.00.5686 |
0.322 |
|
| 2005 |
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8664-70. PMID 16260700 DOI: 10.1200/Jco.2005.01.6071 |
0.352 |
|
| 2005 |
Yu ZF, Catalano PJ. Quantitative risk assessment for multivariate continuous outcomes with application to neurotoxicology: the bivariate case. Biometrics. 61: 757-66. PMID 16135027 DOI: 10.1111/J.1541-0420.2005.00350.X |
0.309 |
|
| 2005 |
Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 Journal of Clinical Oncology. 23: 4897-4904. PMID 16051944 DOI: 10.1200/Jco.2005.03.616 |
0.353 |
|
| 2005 |
Cohen SJ, Dobelbower R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology, Biology, Physics. 62: 1345-50. PMID 16029791 DOI: 10.1016/J.Ijrobp.2004.12.074 |
0.351 |
|
| 2004 |
Giantonio BJ, Chen HX, Catalano PJ, Meropol NJ, O'Dwyer PJ, Benson AI. Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3017. PMID 28015163 DOI: 10.1200/Jco.2004.22.14_Suppl.3017 |
0.341 |
|
| 2004 |
Benson AB, Catalano PJ. A rose, is a rose, is a rose...or not. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1773-5. PMID 15067029 DOI: 10.1200/Jco.2004.02.946 |
0.362 |
|
| 2004 |
Faes C, Geys H, Aerts M, Molenberghs G, Catalano PJ. Modeling combined continuous and ordinal outcomes in a clustered setting Journal of Agricultural, Biological, and Environmental Statistics. 9: 515-530. DOI: 10.1198/108571104X16349 |
0.302 |
|
| 2003 |
Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Annals of Internal Medicine. 139: 649-57. PMID 14568853 DOI: 10.7326/0003-4819-139-8-200310210-00008 |
0.339 |
|
| 2003 |
Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): An eastern cooperative oncology group study Medical Oncology. 20: 137-145. PMID 12835516 DOI: 10.1385/Mo:20:2:137 |
0.354 |
|
| 2003 |
Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer. 97: 1869-75. PMID 12673712 DOI: 10.1002/Cncr.11271 |
0.312 |
|
| 2003 |
Johnston PG, Benson AB, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 815-9. PMID 12610179 DOI: 10.1200/Jco.2003.07.039 |
0.339 |
|
| 2003 |
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 433-40. PMID 12560431 DOI: 10.1200/Jco.2003.07.125 |
0.306 |
|
| 2002 |
Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clinical Colorectal Cancer. 2: 43-50. PMID 12453335 DOI: 10.3816/Ccc.2002.N.010 |
0.373 |
|
| 2002 |
McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. Journal of the National Cancer Institute. 94: 1160-7. PMID 12165641 DOI: 10.1093/Jnci/94.15.1160 |
0.375 |
|
| 2002 |
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3270-5. PMID 12149301 DOI: 10.1200/Jco.2002.11.149 |
0.367 |
|
| 2002 |
Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-α-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296 Cancer Journal. 8: 282-286. PMID 12074329 DOI: 10.1097/00130404-200205000-00013 |
0.331 |
|
| 2002 |
Malone T, Catalano PJ, O'Dwyer PJ, Giantonio B. High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience. Journal of the National Cancer Institute. 94: 769-71. PMID 12011228 DOI: 10.1093/Jnci/94.10.769 |
0.305 |
|
| 2002 |
Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G. Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. 20: 1859-1863. PMID 11919245 DOI: 10.1200/Jco.2002.07.158 |
0.337 |
|
| 2002 |
Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Annals of Internal Medicine. 136: 261-9. PMID 11848723 DOI: 10.7326/0003-4819-136-4-200202190-00005 |
0.336 |
|
| 2001 |
Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, Hamilton SR. Molecular predictors of survival after adjuvant chemotherapy for colon cancer New England Journal of Medicine. 344: 1196-1206. PMID 11309634 DOI: 10.1056/Nejm200104193441603 |
0.331 |
|
| 2000 |
Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3384-9. PMID 11013279 DOI: 10.1200/Jco.2000.18.19.3384 |
0.372 |
|
| 1999 |
Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 569-77. PMID 10080601 DOI: 10.1200/Jco.1999.17.2.569 |
0.307 |
|
| 1998 |
Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and cancer and leukemia group B study Journal of Clinical Oncology. 16: 1287-1293. PMID 9552027 DOI: 10.1200/Jco.1998.16.4.1287 |
0.358 |
|
| 1993 |
Catalano PJ, Scharfstein DO, Ryan LM, Kimmel CA, Kimmel GL. Statistical model for fetal death, fetal weight, and malformation in developmental toxicity studies Teratology. 47: 281-290. PMID 8322222 DOI: 10.1002/Tera.1420470405 |
0.304 |
|
| Show low-probability matches. |